Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer

Small cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of poly (ADP-ribose) polymerase (PARP) have modest single-agent activity. We performed a phase I/II trial of combination olaparib tablets and temozolomide (OT) in previously treated SCLC. We established a recommended phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Farago, Anna F., Yeap, Beow Y., Stanzione, Marcello, Hung, Yin P., Heist, Rebecca S., Marcoux, J. Paul, Zhong, Jun, Rangachari, Deepa, Barbie, David A., Phat, Sarah, Myers, David T., Morris, Robert, Kem, Marina, Dubash, Taronish D., Kennedy, Elizabeth A., Digumarthy, Subba R., Sequist, Lecia V., Hata, Aaron N., Maheswaran, Shyamala, Haber, Daniel A, Lawrence, Michael S, Shaw, Alice T., Mino-Kenudson, Mari, Dyson, Nicholas J., Drapkin, Benjamin J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7319046/
https://ncbi.nlm.nih.gov/pubmed/31416802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0582
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados